NEW YORK (GenomeWeb) – Sophia Genetics and Genycell Biotech today announced a partnership to expand access to the Sophia Data Driven Medicine (Sophia DDM) platform.
As part of the deal, Genycell will distribute Sophia DDM as part of a package to laboratories and hospitals in Spain and Portugal performing next-generation sequencing-based clinical diagnosis, a Sophia spokesman said. Sophia DDM uses machine learning and algorithms for genomic analysis of patient samples.
Earlier this month, the Swiss firm announced partnerships with three institutions in Spain to accelerate the adoption of NGS tests.
"Thanks to today's partnership with Genycell Biotech, we should see additional Spanish and Portuguese hospitals soon performing NGS-based diagnostics for improving care for thousands of patients every year," Sophia CEO and Co-Founder Jurgi Camblong said in a statement.